Tatyana Dronova

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/8621669/publications.pdf

Version: 2024-02-01

11	57	1683354 5	1588620 8
papers	citations	h-index	g-index

11	11	11	67
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Predictive value of vascular endothelial growth factor receptor type 2 in triple-negative breast cancer patients treated with neoadjuvant chemotherapy. Molecular and Cellular Biochemistry, 2018, 444, 197-206.	1.4	16
2	The distribution pattern of ERÎ± expression, ESR1 genetic variation and expression of growth factor receptors: association with breast cancer prognosis in Russian patients treated with adjuvant tamoxifen. Clinical and Experimental Medicine, 2017, 17, 383-393.	1.9	10
3	Impact of estrogen receptor Î± on the tamoxifen response and prognosis in luminal-A-like and luminal-B-like breast cancer. Clinical and Experimental Medicine, 2019, 19, 547-556.	1.9	10
4	Role of TGF-Î² signaling in the mechanisms of tamoxifen resistance. Cytokine and Growth Factor Reviews, 2021, 62, 62-69.	3.2	8
5	Relation of EGFR/PI3K/AKT signaling components with tamoxifen efficacy in patients with estrogen-dependent breast cancer. Uspehi Molekularnoj Onkologii, 2018, 5, 40-50.	0.1	6
6	Vascular Endothelial Growth Factor Receptor 2 (VEGFR2) Contributes to Tamoxifen Resistance in Estrogen-Positive Breast Cancer Patients. Molecular Biology, 2021, 55, 102-108.	0.4	3
7	PI3K/AKT/MTOR: CONTRIBUTION TO THE TUMOR PHENOTYPE SENSITIVE TO TAMOXIFEN. , 2021, 20, 16-23.	0.3	2
8	The role of epidermal growth factor receptor (EGFR) in the efficacy of neoadjuvant chemotherapy in triple-negative breast cancer patients. Bulletin of Siberian Medicine, 2020, 19, 13-20.	0.1	2
9	Non-Smad TGF-Î² signaling components are possible biomarkers of tamoxifen resistance. AIP Conference Proceedings, 2017, , .	0.3	0
10	Abstract 562: Impact of ERÎ± expression status and ESR1 genetic variation on progression in tamoxifen-treated breast cancer patients. , 2014, , .		0
11	ROLE OF CYCLIN D1 IN THE MECHANISMS OF TAMOXIFEN RESISTANCE. Siberian Journal of Oncology, 2020, 19, 138-145.	0.1	0